Participated in a smaller group of the FDA Team (JonoRoss - GeoScience Australia, Bianca Hoersch ? ESA, Rob Woodcock - CSIRO, Brian Killough - SEO) to do the analysis and writing of materials of the FDA Strategic Assessment Survey. In particular, this first analysis is looking to present the findings surrounding the question ?What should CEOS agencies do together? in regards to FDA. The findings were presented at the SIT-32 meeting in Paris.
After the ad hoc team presents the FDA objectives and implementation plan to the principals for endorsement at the 2017 CEOS Plenary, WGISS will then begin developing best practices for FDA. Until then, it was agreed to move the completion date of this action to Q2 2018.
This action was closed in the CEOS WP 2018-2020 as subsumed into more defined FDA actions carried by WGISS or the FDA AHT.